Hepatitis C virus vaccines - Progress and perspectives

Microbial Pathogenesis

Volumn 58, Issue , 2013, Pages 66-72

  Fauvelle, Catherine ^a,b   Lepiller, Quentin ^a,b,c   Felmlee, Daniel J ^a,b   Fofana, Isabel ^a,b   Habersetzer, François ^a,b,c   Stoll Keller, Françoise ^a,b,c   Baumert, Thomas F ^a,b,c   Fafi Kremer, Samira ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Hepatitis C virus; Immune response; Vaccine candidates; Viral evasion

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS VACCINE; VIROSOME VACCINE; VIRUS VECTOR;

ADAPTIVE IMMUNITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMPANZEE; DISEASE MODEL; HEPATITIS C; HUMAN; IMMUNE EVASION; INNATE IMMUNITY; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; VIRAL CLEARANCE; VIRAL GENE DELIVERY SYSTEM; VIRION; VIROLOGY; VIRUS GENOME; VIRUS IMMUNITY; VIRUS PARTICLE;

ANIMALS; DRUG DISCOVERY; HEPACIVIRUS; HEPATITIS C; VIRAL VACCINES;

ANIMALIA; HEPATITIS C VIRUS;

EID: 84875855315     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2013.02.005     Document Type: Review

References (89)

1. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46.
2. Muhlberger N., Schwarzer R., Lettmeier B., Sroczynski G., Zeuzem S., Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
3. Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 2012, 142:1279-1287. e3.
4. Davis G.L., Alter M.J., El-Serag H., Poynard T., Jennings L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2009, 138:513-521. 21 e1-6.
5. World Hepatitis Alliance Viral hepatitis: global policy 2010, http://www.worldhepatitis%20alliance.%20org/Libraries/Campaign_Materials/Viral_Hepatitis_Global_Policy.sflb.ashx.
6. Vellozzi C., Buchacz K., Baker R., Spradling P.R., Richardson J., Moorman A., et al. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV outpatient study (HOPS), 1999-2007. J Viral Hepat 2011, 18:316-324.
7. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004, 85:3173-3188.
8. Cornberg M., Razavi H.A., Alberti A., Bernasconi E., Buti M., Cooper C., et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011, 31(Suppl. 2):30-60.
9. Khattab M.A., Ferenci P., Hadziyannis S.J., Colombo M., Manns M.P., Almasio P.L., et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011, 54:1250-1262.
10. Sievert W., Altraif I., Razavi H.A., Abdo A., Ahmed E.A., Alomair A., et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(Suppl. 2):61-80.
11. Lee L.Y., Tong C.Y., Wong T., Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012, 66:342-355.
12. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008, 5:610-622.
13. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
14. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
15. World Health Organization Prevention and control of viral hepatitis infection: framework for global action 2012, http://www.who.int/entity/csr/disease/hepatitis/GHP_%20framework.pdf.
16. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
17. Ni Y.H., Huang L.M., Chang M.H., Yen C.J., Lu C.Y., You S.L., et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007, 132:1287-1293.
18. Di Lorenzo C., Angus A.G., Patel A.H. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011, 3:2280-2300.
19. Khaliq S., Jahan S., Pervaiz A. Sequence variability of HCV core region: important predictors of HCV induced pathogenesis and viral production. Infect Genet Evol 2011, 11:543-556.
20. Vieyres G., Thomas X., Descamps V., Duverlie G., Patel A.H., Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010, 84:10159-10168.
21. Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol 2007, 13:2406-2415.
22. Bartenschlager R., Penin F., Lohmann V., Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011, 19:95-103.
23. Thimme R., Binder M., Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012, 36:663-683.
24. Feinstone S.M., Hu D.J., Major M.E. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin Infect Dis 2012, 55(Suppl. 1):S25-S32.
25. Halliday J., Klenerman P., Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011, 10:659-672.
26. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001, 194:1395-1406.
27. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000, 191:1499-1512.
28. Osburn W.O., Fisher B.E., Dowd K.A., Urban G., Liu L., Ray S.C., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138:315-324.
29. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006, 44:1139-1145.
30. Dustin L.B., Rice C.M. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007, 25:71-99.
31. Gale M., Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436:939-945.
32. Lambotin M., Raghuraman S., Stoll-Keller F., Baumert T.F., Barth H. A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol 2010, 8:350-360.
33. Cheent K., Khakoo S.I. Natural killer cells and hepatitis C: action and reaction. Gut 2011, 60:268-278.
34. Arens R. Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors. Adv Immunol 2012, 114:217-243.
35. Zhou Y., Zhang Y., Yao Z., Moorman J.P., Jia Z. Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology 2012, 136:385-396.
36. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1745-1754.
37. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999, 117:933-941.
38. Urbani S., Amadei B., Fisicaro P., Tola D., Orlandini A., Sacchelli L., et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006, 44:126-139.
39. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002, 99:15661-15668.
40. Fafi-Kremer S., Fauvelle C., Felmlee D.J., Zeisel M.B., Lepiller Q., Fofana I., et al. Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses 2012, 4:2016-2030.
41. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.L., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007, 104:6025-6030.
42. Raghuraman S., Park H., Osburn W.O., Winkelstein E., Edlin B.R., Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012, 205:763-771.
43. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008, 14:25-27.
44. Ndongo N., Berthillon P., Pradat P., Vieux C., Bordes I., Berby F., et al. Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus. Hepatology 2010, 52:1531-1542.
45. Lin W., Kim S.S., Yeung E., Kamegaya Y., Blackard J.T., Kim K.A., et al. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 2006, 80:9226-9235.
46. Kumthip K., Chusri P., Jilg N., Zhao L., Fusco D.N., Zhao H., et al. Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol 2012, 86:8581-8591.
47. von Hahn T., Yoon J.C., Alter H., Rice C.M., Rehermann B., Balfe P., et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132:667-678.
48. Fofana I., Fafi-Kremer S., Carolla P., Fauvelle C., Zahid M.N., Turek M., et al. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 2012, 143:223-233. e9.
49. Brimacombe C.L., Grove J., Meredith L.W., Hu K., Syder A.J., Flores M.V., et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011, 85:596-605.
50. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003, 197:633-642.
51. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
52. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11:791-796.
53. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006, 103:7408-7413.
54. Gastaminza P., Kapadia S.B., Chisari F.V. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 2006, 80:11074-11081.
55. Murray C.L., Rice C.M. Turning hepatitis C into a real virus. Annu Rev Microbiol 2011, 65:307-327.
56. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994, 91:7792-7796.
57. Zhang P., Zhong L., Struble E.B., Watanabe H., Kachko A., Mihalik K., et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A 2009, 106:7537-7541.
58. Barth H., Rybczynska J., Patient R., Choi Y., Sapp R.K., Baumert T.F., et al. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology 2011, 54:1135-1148.
59. Meunier J.C., Gottwein J.M., Houghton M., Russell R.S., Emerson S.U., Bukh J., et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011, 204:1186-1190.
60. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001, 7:927-933.
61. Meuleman P., Hesselgesser J., Paulson M., Vanwolleghem T., Desombere I., Reiser H., et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008, 48:1761-1768.
62. Meuleman P., Bukh J., Verhoye L., Farhoudi A., Vanwolleghem T., Wang R.Y., et al. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011, 53:755-762.
63. Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
64. Bissig K.D., Wieland S.F., Tran P., Isogawa M., Le T.T., Chisari F.V., et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010, 120:924-930.
65. de Jong Y.P., Rice C.M., Ploss A. New horizons for studying human hepatotropic infections. J Clin Invest 2010, 120:650-653.
66. Dorner M., Rice C.M., Ploss A. Study of hepatitis C virus entry in genetically humanized mice. Methods 2012, 59:249-257.
67. Washburn M.L., Bility M.T., Zhang L., Kovalev G.I., Buntzman A., Frelinger J.A., et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011, 140:1334-1344.
68. Bility M.T., Zhang L., Washburn M.L., Curtis T.A., Kovalev G.I., Su L. Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis. Nat Protoc 2012, 7:1608-1617.
69. Stoll-Keller F., Barth H., Fafi-Kremer S., Zeisel M.B., Baumert T.F. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 2009, 8:333-345.
70. Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 1994, 91:1294-1298.
71. Frey S.E., Houghton M., Coates S., Abrignani S., Chien D., Rosa D., et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010, 28:6367-6373.
72. Stamataki Z., Coates S., Abrignani S., Houghton M., McKeating J.A. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis 2011, 204:811-813.
73. Law J, Chen C, Hockman D, Frey S, Belshe R, Wakita T, et al. Recombinant glycoproteins E1/E2 vaccine from a single HCV strain elicit broadly cross-neutralizing antibodies against major HCV genotypes in human. In: 19th International symposium on hepatitis C virus and related viruses; 2012.
74. Drane D., Maraskovsky E., Gibson R., Mitchell S., Barnden M., Moskwa A., et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin 2009, 5:151-157.
75. Beaumont E., Patient R., Hourioux C., Dimier-Poisson I., Roingeard P. Chimeric HBV-HCV envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology 2012, 10.1002/hep.26132.
76. Baumert T.F., Ito S., Wong D.T., Liang T.J. Hepatitis C virus structural proteins assemble into virus like particles in insect cells. J Virol 1998, 72:3827-3836.
77. Murata K., Lechmann M., Qiao M., Gunji T., Alter H.J., Liang T.J. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A 2003, 100:6753-6758.
78. Jeong S.H., Qiao M., Nascimbeni M., Hu Z., Rehermann B., Murthy K., et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004, 78:6995-7003.
79. Elmowalid G.A., Qiao M., Jeong S.H., Borg B.B., Baumert T.F., Sapp R.K., et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 2007, 104:8427-8432.
80. Chua B.Y., Johnson D., Tan A., Earnest-Silveira L., Sekiya T., Chin R., et al. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One 2012, 7:e47492.
81. Garrone P., Fluckiger A.C., Mangeot P.E., Gauthier E., Dupeyrot-Lacas P., Mancip J., et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011, 3:94ra71.
82. Reyes-Del Valle J., de la Fuente C., Turner M.A., Springfeld C., Apte-Sengupta S., Frenzke M.E., et al. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol 2012, 86:11558-11566.
83. Acres B., Bonnefoy J.Y. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccin 2008, 7:889-893.
84. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428:182-185.
85. Earl P.L., Americo J.L., Wyatt L.S., Espenshade O., Bassler J., Gong K., et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A 2008, 105:10889-10894.
86. Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008, 38:732-741.
87. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4:115ra2.
88. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006, 12:190-197.
89. Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012, 4:115ra1.